Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-25-000088
Filing Date
2025-08-13
Accepted
2025-08-13 16:14:06
Documents
73
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20250630.htm   iXBRL 10-Q 1499012
2 EX-31.1 allo-20250630xex311.htm EX-31.1 9635
3 EX-31.2 allo-20250630xex312.htm EX-31.2 9585
4 EX-32.1 allo-20250630xex321.htm EX-32.1 6895
  Complete submission text file 0001737287-25-000088.txt   7405676

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20250630.xsd EX-101.SCH 55706
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20250630_cal.xml EX-101.CAL 58803
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20250630_def.xml EX-101.DEF 352061
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20250630_lab.xml EX-101.LAB 691997
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20250630_pre.xml EX-101.PRE 510096
75 EXTRACTED XBRL INSTANCE DOCUMENT allo-20250630_htm.xml XML 864801
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 251211765
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)